GlassScriptPhysician profile
Rosemary Son
NPI 1609190503
$18,450.93
in general payments reported to CMS, 2019-2025
20 companies · $7,305 in 2025
The $7,305 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $846 · 2023: $4,044 · 2024: $6,069 · 2025: $7,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,153 · Consulting Fee: $5,120 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,930 · Travel and Lodging: $135 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,152.74 |
| Consulting Fee | $5,120.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,930.00 |
| Travel and Lodging | $134.60 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,505.14 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,349.65 | 2023-2025 | |
| Incyte Corporation | $1,543.81 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $1,446.47 | 2024-2025 | Adbry, Spevigo, Anzupgo |
| Amgen INC. | $1,063.07 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $1,031.57 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $688.81 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $605.28 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $496.29 | 2023-2024 | Vtama |
| Lilly USA, LLC | $481.36 | 2024-2025 | Ebglyss, Olumiant |
| Pfizer INC. | $420.79 | 2023-2024 | |
| Ucb, INC. | $413.05 | 2022-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $403.76 | 2023-2025 | Tremfya |
| Almirall LLC | $241.93 | 2024 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $241.89 | 2022-2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $241.12 | 2022-2023 | Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.11 | 2024-2025 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $80.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Galderma Laboratories, L.P. | $15.64 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.